Clinical Trial Update: Voriconazole For Chronic Bronchopulmonary Aspergillosis [Phase 2, Phase 3]

View source ↗

Summary

Pfizer-sponsored Phase 2/3 trials evaluated voriconazole for chronic bronchopulmonary aspergillosis. The results were posted in January 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Bronchopulmonary Aspergillosis

Drugs mentioned

• VORICONAZOLE (Voriconazole)

Snippet

Sponsor: Pfizer | Conditions: Aspergillosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2010-01-07